drugset / Trial / NCT06462326

A Study to Compare the Effect of Omadacycline Versus Moxifloxacin in Healthy Adult Volunteers

NCT06462326

Phase 1 Completed 24 enrolled Zai Lab
RandomizedParallel-groupTriple-blindHealth-services research

Summary

This is a randomized (1:1), double-blind, double-dummy, phase I study to compare the effects of Omadacycline versus Moxifloxacin on gut microbiota and the resistomes in healthy adult volunteers.The study consists of 3 phases: Screening, double-blind treatment, and follow-up. Healthy volunteers aged 18-40 years, who meet entry criteria, are randomly assigned to a treatment group using an Interactive Voice Response System/Interactive Web Response System (IxRS) and receive the first dose of the study drug.

Timeline

Start
2024-04-16
Primary completion
2024-09-29
Completion
2024-09-29

Drugs

EvaluationDrugModalityDoseRoute
Comparator Moxifloxacin Small molecule 400 mg Oral
Subject Omadacycline Small molecule 300 mg Oral

Indications

No indication recorded.